Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia - PubMed (original) (raw)
Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia
A R Varma et al. J Neurol Neurosurg Psychiatry. 1999 Feb.
Abstract
Objectives: The diagnosis of Alzheimer's disease (AD) is now reliant on the use of NINCDS-ADRDA criteria. Other diseases causing dementia are being increasingly recognised--for example, frontotemporal dementia (FTD). Historically, these disorders have not been clearly demarcated from AD. This study assesses the capability of the NINCDS-ADRDA criteria to accurately distinguish AD from FTD in a series of pathologically proved cases.
Methods: The case records of 56 patients (30 with AD, 26 with FTD) who had undergone neuropsychological evaluation, brain imaging, and ultimately postmortem, were assessed in terms of whether at initial diagnosis the NINCDS-ADRDA criteria were successful in diagnosing those patients who had AD and excluding those who did not.
Results: (1) The overall sensitivity of the NINCDS-ADRDA criteria in diagnosing "probable" AD from 56 patients with cortical dementia (AD and FTD) was 0.93. However, the specificity was only 0.23; most patients with FTD also fulfilled NINCDS-ADRDA criteria for AD. (2) Cognitive deficits in the realms of orientation and praxis significantly increased the odds of a patient having AD compared with FTD, whereas deficits in problem solving significantly decreased the odds. Neuropsychological impairments in the domains of attention, language, perception, and memory as defined in the NINCDS-ADRDA statement did not contribute to the clinical differentiation of AD and FTD.
Conclusion: NINCDS-ADRDA criteria fail accurately to differentiate AD from FTD. Suggestions to improve the diagnostic specificity of the current criteria are made.
Similar articles
- The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach.
Hogervorst E, Bandelow S, Combrinck M, Irani SR, Smith AD. Hogervorst E, et al. Dement Geriatr Cogn Disord. 2003;16(3):170-80. doi: 10.1159/000071006. Dement Geriatr Cogn Disord. 2003. PMID: 12826744 - Patterns of cognitive impairment in Alzheimer's disease: assessment and differential diagnosis.
Storey E, Slavin MJ, Kinsella GJ. Storey E, et al. Front Biosci. 2002 May 1;7:e155-84. doi: 10.2741/A914. Front Biosci. 2002. PMID: 11991855 Review. - Frontotemporal dementia and Alzheimer's disease: differential diagnosis.
Duara R, Barker W, Luis CA. Duara R, et al. Dement Geriatr Cogn Disord. 1999;10 Suppl 1:37-42. doi: 10.1159/000051210. Dement Geriatr Cogn Disord. 1999. PMID: 10436338 Review.
Cited by
- Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer's disease.
Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N, Meijers-Heijboer H, Huisman M, Scheltens P, Reinders MJT, van der Flier WM, Holstege H. Tesi N, et al. Eur J Hum Genet. 2019 Feb;27(2):244-253. doi: 10.1038/s41431-018-0273-5. Epub 2018 Sep 26. Eur J Hum Genet. 2019. PMID: 30258121 Free PMC article. - Neuroimaging in dementia.
Vitali P, Migliaccio R, Agosta F, Rosen HJ, Geschwind MD. Vitali P, et al. Semin Neurol. 2008 Sep;28(4):467-83. doi: 10.1055/s-0028-1083695. Epub 2008 Oct 8. Semin Neurol. 2008. PMID: 18843575 Free PMC article. Review. - The Early-Onset Alzheimer's Disease Whole-Genome Sequencing Project: Study design and methodology.
Ray NR, Ayodele T, Jean-Francois M, Baez P, Fernandez V, Bradley J, Crane PK, Dalgard CL, Kuzma A, Nicaretta H, Sims R, Williams J, Cuccaro ML, Pericak-Vance MA, Mayeux R, Wang LS, Schellenberg GD, Cruchaga C, Beecham GW, Reitz C. Ray NR, et al. Alzheimers Dement. 2023 Sep;19(9):4187-4195. doi: 10.1002/alz.13370. Epub 2023 Jun 30. Alzheimers Dement. 2023. PMID: 37390458 Free PMC article. - Alzheimer's disease neuropathologic changes in semantic dementia.
Chow TW, Varpetian A, Moss T, Vinters HV, Marquez S, Miller C. Chow TW, et al. Neurocase. 2010 Feb;16(1):15-22. doi: 10.1080/13554790903193174. Epub 2009 Oct 28. Neurocase. 2010. PMID: 19866390 Free PMC article. - Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease.
Wolk DA, Dickerson BC; Alzheimer's Disease Neuroimaging Initiative. Wolk DA, et al. Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10256-61. doi: 10.1073/pnas.1001412107. Epub 2010 May 17. Proc Natl Acad Sci U S A. 2010. PMID: 20479234 Free PMC article.
References
- J Psychiatr Res. 1975 Nov;12(3):189-98 - PubMed
- J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):11-21 - PubMed
- Arch Neurol. 1986 Mar;43(3):239-46 - PubMed
- J Neurol Neurosurg Psychiatry. 1986 Feb;49(2):163-74 - PubMed
- AJR Am J Roentgenol. 1986 Dec;147(6):1313-8 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical